What Vesalius Longevity Labs does

Vesalius Longevity Labs is a U.S.-based peptide therapeutics company founded in November 2024 and headquartered in Scottsdale, Arizona, that distributes a premium portfolio of peptide bioregulators under the Peptual brand through a B2Doctor ecosystem. Its product line spans multiple delivery modalities — injectables, transdermal patches, nasal sprays, oral peptides, and topical formulations — primarily sourced and manufactured in the U.S. at FDA-registered, cGMP-compliant facilities, and is positioned to address longevity, health optimization, anti-aging, and (through the Wisp partnership) women's reproductive and hormonal health including fertility and menopause. The company was co-founded by Dr. Matt Cook, a regenerative medicine authority, and Jennifer Benson, a Board Certified Integrative Holistic Health Practitioner; its leadership team includes CEO Dr. Pradeep Albert, CCO Timmi Stump, and COO Ted Stover, with an incoming CEO (Kevin Rabbitt) and reconstituted board set to take effect upon closing of the reverse takeover with Sweet Earth Holdings Corporation.

The business operates a hybrid GTM model: a global enterprise field-sales motion distributing product through an independent licensed healthcare provider network across North America, Europe, UAE, Asia Pacific, Latin America, and Australia, augmented by a channel-partner motion via Wisp, the largest pure-play women's telehealth provider in the U.S. (1.5M+ patients), for direct-to-consumer reach launching in early 2026. Revenue is generated through one-time product sales to providers and (via partners) to consumers; no direct pricing is publicly disclosed. The company is going public through a reverse takeover with Sweet Earth Holdings (CSE: SE), with the transaction expected to close in Q3 2025 and former Vesalius shareholders to hold approximately 80% of the combined entity, supported by approximately $19.4M in cumulative private placement proceeds. Marketing leverages wellness influencer endorsements (Ben Greenfield, Gary Brecka, Chris Bumstead, George Kittle), content marketing, Instagram, email, and PR, with the Scientific Advisory Board expanded in July 2025 to include Shane Bakker and Dean Henry.

Name

Vesalius Longevity Labs

Legal name

Vesalius, Inc.

Website

https://vesaliuslabs.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Vesalius Longevity Labs is a Scottsdale-based peptide therapeutics company that distributes its premium Peptual product line (injectables, patches, nasal sprays, oral peptides, topicals) through a global B2Doctor network of independent licensed providers and, via Wisp, women's telehealth, targeting longevity and women's health.

Ownership category

akta.pro rank

Product category

Peptide Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity) (CRADAGAE)

akta.pro secondary industry

Women’s Health Supplements (Prenatal, Menopause, Hormonal) (CRADAGAK)

Keywords

• Peptide therapeutics
• Longevity medicine
• Bioregulator products
• Regenerative peptides
• Wellness supplements

Headquarters

HQ city

Scottsdale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. B2Doctor Product Sales: Sale of peptide products and bioregulators through a global network of independent licensed healthcare providers. The company provides an end-to-end ecosystem including product fulfillment, with products distributed via doctor's offices and health professionals.
2. Consumer Product Sales (via partners): Sale of peptide products directly to consumers through partnership channels, including telehealth providers like Wisp. Products include supplements and therapeutics targeting longevity, fertility, and menopause.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Vesalius Longevity Labs develops and distributes premium peptide and bioregulator products under its Peptual product line, offered in multiple delivery formats including injectables, patches, nasal sprays, oral peptides, and topical formulations. Products are sold primarily to independent licensed healthcare providers through a global B2Doctor ecosystem with product fulfillment and education support, and to consumers via strategic telehealth partnerships (notably Wisp for women's health).

Product overview

Vesalius Longevity Labs operates as a peptide science company offering its Peptual branded product line—the company's core offering—which includes injectables, patches, nasal sprays, oral peptides, and topical formulations distributed through a global B2Doctor ecosystem of licensed healthcare providers. Through a strategic partnership with Wisp, the company is expanding into women's-specific peptide therapeutics (Women's Peptide Therapeutics sub-brand) targeting fertility and menopause, expected to launch in early 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Peptual: Premium line of peptides and bioregulators including injectables, patches, nasal sprays, oral peptides, and topical formulations.

Products and services

• Peptual Product Line Peptual is Vesalius' flagship product line of premium peptides and bioregulators offered in multiple delivery formats (injectables, patches, nasal sprays, oral peptides, topical formulations). It is sold to and through independent licensed healthcare providers worldwide for use in longevity, health optimization, and anti-aging protocols, and is U.S.-sourced and manufactured in FDA-registered, cGMP-compliant facilities.
• Women's Peptide Therapeutics A sub-brand under development that leverages the Peptual formulations (injectables, patches, nasal sprays, topical formulations) to create a dedicated women's health peptide portfolio targeting fertility and menopause, distributed via the Wisp telehealth platform serving over 1.5 million patients.

Quantifiable outcome

• Peptide therapeutics market growing from $43.1B (2023) to $106B by 2033 at 10.8% CAGR
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• WispcoreStrategic or Co-development Partner · 9 October 2025Strategic partnership between Vesalius Longevity Labs and Wisp, the largest pure play women's telehealth provider in the U.S., to develop and launch an exclusive range of peptide therapeutics designed for women's health needs including fertility and menopause. The collaboration leverages Vesalius' Peptual product line and Wisp's digital care infrastructure to address the gender gap in longevity care. Products are planned for launch in early 2026. The companies will also jointly evaluate emerging longevity AI platforms for potential integration and explore strategic investments in AI tools for personalized care and clinical decision support.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Wisp: Largest pure-play women's telehealth provider in the U.S. serving 1.5M+ patients. Partnered with Vesalius to launch women's peptide therapeutics for fertility and menopause; comparable in telehealth infrastructure, women's health focus, and consumer prescription delivery model.
• Defy Medical: Telehealth clinic specializing in hormone replacement, peptide therapy, and wellness treatments prescribed by physicians and shipped directly to patients. Closely aligned with Vesalius' prescriber-mediated peptide distribution model and longevity focus.
• Hone Health: Direct-to-consumer telehealth platform offering hormone optimization, peptide therapy, and longevity treatments prescribed by licensed physicians. Directly comparable to Vesalius' B2Doctor + telehealth model and overlapping product categories (longevity peptides, hormone-related therapeutics).
• Marek Health: Online men's health and longevity platform offering hormone therapy, peptides, and performance optimization through licensed providers. Comparable consumer-prescriber model and overlapping peptide portfolio targeting similar affluent, health-optimization customer segments.
• BioTE Medical: Medical-grade hormone optimization and peptide therapy company with a large network of certified providers. Comparable B2Doctor commercial model, broad provider education program, and adjacency in wellness/restorative therapy markets.
• AgelessRx: Telehealth longevity clinic offering prescription peptides, NAD+, and anti-aging therapies to consumers nationwide. Most direct overlap with Vesalius' Peptual line on the consumer-facing peptide prescribing and distribution side.

Broad incumbents

• Eli Lilly (Mounjaro / Zepbound): Global pharmaceutical leader whose tirzepatide franchises (Mounjaro, Zepbound) are peptide-based and have driven mainstream validation of peptide therapeutics. Sets the public-market benchmark for peptide therapeutic value capture, even though the products and indications differ from Vesalius' longevity focus.
• Life Extension: Long-established direct-to-consumer supplements brand with a strong longevity clinical franchise, including hormone and peptide-adjacent products. Comparable customer demographic and longevity/health-optimization positioning, but a much broader portfolio spanning vitamins, supplements, and diagnostics.
• Thorne: Large, well-established supplements and health-optimization brand offering practitioner-grade nutritional supplements, including some peptide-related formulations. Comparable premium supplement positioning, practitioner channel, and longevity/healthspan audience, though broader in scope than Vesalius' peptide focus.

Emerging players

• Midi Health: Women's midlife and menopause-focused virtual care clinic offering hormone therapy and wellness programs. Directly comparable to the women's health sub-brand Vesalius is launching with Wisp, and a relevant emerging competitor in the same demographic and indication space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/vesalius.longevity

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vesalius Longevity Labs